title: Laryngeal contact granuloma.
abstract: OBJECTIVE
  To report outcomes of treatment for laryngeal contact granuloma.
  
  
  METHODS
  Prospective treatment of 21 patients with laryngeal contact granulomas using proton-pump inhibitor (PPI) medication.
  
  
  METHODS
  Patients were diagnosed and followed by office endoscopy and patient interview.
  
  
  RESULTS
  Three patients did not tolerate PPI medication and were managed by treatment with type 2 histamine (H2) blockers. The lesion completely resolved in 14 of the 18 patients maintained on PPI medication, and significantly regressed in the other 4. Residual granulomas were surgically excised in one patient. Lesions resolved in two patients following injection of botulinum toxin into one thyroarytenoid muscle. One patient had a residual lesion, but symptoms were controlled by medication, and he declined treatment with botulinum toxin. Of the three patients treated with H2-blocker medication, the lesion resolved in only one.
  
  
  CONCLUSIONS
  PPI medication is effective in the treatment of laryngeal contact granuloma, even in the absence of identifiable symptoms of gastroesophageal reflux.
authors.affiliation: Department of Otolaryngology, University of Tennessee, Memphis, School of Medicine, 38163, USA.
authors.forename: M K
authors.initials: MK
authors.lastname: Wani
authors.forename: G E
authors.initials: GE
authors.lastname: Woodson
mesh_terms: D000328:Adult; D000368:Aged; D018726:Anti-Dyskinesia Agents / Q000627:therapeutic use; D001905:Botulinum Toxins / Q000627:therapeutic use; D005260:Female; D006099:Granuloma / Q000188:drug therapy*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy*; D007978:Levamisole / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use*; D011446:Prospective Studies; D054328:Proton Pump Inhibitors; D011899:Ranitidine / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D018726:Anti-Dyskinesia Agents; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors; D007978:Levamisole; D011899:Ranitidine; D001905:Botulinum Toxins; D009853:Omeprazole